[Ip-health] IP-Watch: WHO Neglected Disease R&D Finance Group Nears Recommendations

[IP-Watch]

This is a multi-part message in MIME format.
--
[ Picked text/plain from multipart/alternative ]
http://www.ip-watch.org/weblog/2009/12/07/who-neglected-disease-rd-finance-g
roup-nears-recommendations/#more-8226



Intellectual Property Watch



WHO Neglected Disease R&D Finance Group Nears Recommendations

An expert working group on innovative financing for research and
development, meeting under the auspices of the World Health Organization,
held its third and final meeting last week, with a report from the secretive
group expected to be released to member states in the coming weeks,
according to sources.

The WHO's public health and intellectual property department also
<http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_6-en.pdf> has recently
released a progress report [pdf] on the implementation of the global
strategy and plan of action on public health, innovation and intellectual
property. The progress report details for the WHO Executive Board the
group's activities to date. A separate report on the Quick Start programme
<http://www.who.int/phi/GS_implementQS.pdf> is also available here [pdf].
The programme is part of the global strategy intended to help identify what
activities within WHO related to the strategy were already taking place, to
avoid duplication and aid coordination.

Expert Working Group

The expert R&D financing working group report will contain recommendations
to member states on innovative financing options. The working group looked
through all proposals submitted during
<http://www.who.int/phi/publichearing_rdf/en/index.html> two public
hearings, and ranked them on basis of feasibility and available information,
as some were interesting concepts but lacked detail, others did not seem
workable, and others seemed potentially useful but first needed further
inquiry, a source told Intellectual Property Watch.

The report is being finalised and is expected to come out in the next week,
sources said, though it was unclear if this is to the public or just to
member states. The working group met from 30 November to 2 December.

One of the basic recognitions of the expert working group is that a
substantial amount of money needs to be invested in the development of
products to treat diseases in developing countries, the source told
Intellectual Property Watch. There has been progress in this area, but not
enough to meet needs, and it "should be a bigger priority."

One of the key questions the group had to answer is how to raise funds, as
many proposals for improving R&D on neglected diseases streamline the
research process (and in doing so may cut its costs), but are not actually
revenue-generating, the source said.

For example, patent pools can create "one-stop-shopping" for licences
related to a particular drug, reducing both time and costs associated with
procuring licences individually from their different owners.

Money-making models discussed by the working group seemed to heavily revolve
around taxes, from the drug-procurement group UNITAID's tax on airline
tickets, to the "Tobin tax" that proposes a small surcharge on financial
transactions, to other suggested taxes on goods like tobacco or
pharmaceuticals. There was also discussion of voluntary donations, perhaps
through a fund, a source told Intellectual Property Watch.

It was the clear necessity of finding innovative ways to support R&D that
made many developing country stakeholders see the formation of the working
group as a critical outcome of the global strategy on public health,
innovation and intellectual property. But those same stakeholders have been
concerned about the secrecy of World Health Organization regarding the
activities of the working group since the strategy was adopted by the full
membership in May 2008.

Strengthening Prequalification

The implementation of the global strategy is focussing on three areas:
innovation and access, capacity building, and resource mobilisation and
sustainable financing, Precious Matsoso said to Intellectual Property Watch.
Matsoso leads the public health, innovation and intellectual property
department at WHO, which is responsible for the strategy's implementation.

Initial areas, according to the global strategy report seem to be heavily
focussed on technology transfer and capacity building.

In an attempt to streamline drug registration processes, WHO is working on
strengthening its prequalification plan for medicines. There is "good
potential to support R&D activities [with the prequalification programme]
but this is a new area that should be explored further," said Matsoso.

The report says this strengthening includes expanding the scope of medicines
covered by the programme to include neglected tropical diseases, pandemic
influenza, and reproductive health; adding three more quality-control
laboratories to the programme (bringing the number of labs to eleven).

The medicines department at WHO has been working with UNITAID on a patent
pool, specifically on priority medicines for HIV/AIDS, said Matsoso.

And, in partnership with the United Nations Conference on Trade and
Development (UNCTAD) and the International Centre for Trade and Sustainable
Development (ICTSD), and the support of the European Commission, is
undertaking a project intended to improve access to medicines in developing
countries through local production and technology transfer to aid that
production, Matsoso told Intellectual Property Watch.

It "involves identifying the main challenges and obstacles of local
production in developing countries," she added, and will include both
North-South and South-South technology transfer, and not be limited to
least-developed countries as is the technology transfer article within the
WTO. Initial work will be in stakeholder analysis and case studies, and
preliminary data is expected to be available this week.

Intellectual Property Watch

--